Development and validation of automated immunohistochemistry (IHC) and in-situ hybridization (ISH) oncology biomarker assays as well as special stains in the anatomic pathology and histology department; supporting global CDx studies for pharma clients; adhering to CAP/CLIA accredited clinical trial testing laboratory standards and GxPs.Transferring validated assays into production locally and globally by working collaboratively with scientific team and laboratory technologists; training Histotechnologists with newly implemented methods and instruments; creation of global controlled documents (SOPs, etc.).Taking lead on complex scientific and technical trouble-shooting of the assays and instrumentation as well as scientific global support for laboratory operations; monitoring and ensuring consistent assay performance; establishing and maintaining global tissue bank for complex client inquiries.Facilitated moving CAP/CLIA lab to new site by guiding high efficiency clinical assay transfersResponding to inquiries from numerous departments within the company including global study management as well as clients; liaising technical aspects and project updates; supporting auditor visits.Regularly self-educating about current scientific knowledge and regulatory aspects related to clinical assays and client’s studies.

Developed and validated components, instruments and equipment for immunohistochemistry (IHC) detection systems that are widely used in molecular pathology including in vitro cancer diagnostics and infectious disease diagnostics. Validated an IHC automated system by developing and optimizing protocols and reagents. Collaborative interdepartmental work on multiple projects that involved Production, QC, QA and the Administrative Department of the company while strictly adhering to GLPs, cGMPs and the company’s quality management system. Received training on cell culture of hybridoma cell lines, FPLC for protein purification, chromogenic in situ hybridization (CISH) and high throughput plate reading assays.

Provided exceptional customer service, maintained merchandising standards, executed store operations and acted as gift concierge.

Developed the company’s lead compound, CAR peptide, in the pre-clinical stage. Determined pharmacokinetics of CAR peptide with various methods including spectrofluorometry, chromatography and mass spectrometry (MALDI-TOF and ESI-TOF). Compiled and organized pre-clinical data. Analyzed and interpreted molecular diagnostics data. Assisted with writing NIH grants and contracting new collaborators. Trained interns for the drug development team and coordinated research.

Conducted research on autosomal-dominant polycystic kidney disease in the Weimbs Laboratory. Utilized molecular biology methods including IP, Western Blot and IF. Responsible for passaging and maintaining MDCK and HEK293 cells under sterile conditions using BSL2 cabinets.

Worked independently as well as in a team effort on a 3-semester project to establish a new expression system for biosensors. Endeavors included selection of the expression-platform, cloning and fermentation of Pichia pastoris and analysis of the end-product’s functionality. Gained experience with PCR and DNA transformation techniques.

Supported and guided international visiting and degree-seeking students with administrative matters.

Supported and guided international visiting and degree-seeking students with administrative matters.

Utilized the alga C. reinhardtii as an expression system for allergenic proteins. Established the qualification and quantification of the Bet v 1 protein via RT-PCR, Western-Blot and ELISA. Cultivated and maintained different algae strains. Acquired basic molecular biology skills.

Provided first aid and medical attention. Escorted patients to hospitalization whenever required.